USPTO serial 98131575
EVOX
Reviewed by CopyMark Law Group
Status 653
- Filing date
- Status date
- Registration date
- —
- Examiner
- MORRIS, KRISTINA KLOIBER
- Law office
- TMO LAW OFFICE 116
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EVOX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Oxford, Oxfordshire, GB
Oxford, Oxfordshire, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nancy Sabarra
Nancy Sabarra FROSS ZELNICK LEHRMAN & ZISSU, P.C.151 WEST 42ND ST., 17TH FL.NEW YORK, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations and substances for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein or nucleic acids or viral vectors for therapy; medicine for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; medical preparations for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for medical purposes for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; biological preparations comprising exosome for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations comprising a therapeutic target protein-loaded, nucleic acid-loaded or virus-loaded exosome for the treatment of genetic diseases, respiratory diseases, or cancer; biological preparations comprising exosome sold as a component of pharmaceuticals for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological reagents for medical use; mixed biological preparations for medical purposes for the prevention and treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, extracellular vesicle (EV)-based nucleic acid therapeutics for the prevention and treatment of infections or cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; all of the foregoing excluding such goods or services in the fields of constipation, gut health, weight loss, appetite suppressants, dietetic preparations, and nutrition | ACTIVE | — |
| 042 | Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; research and analysis services in the field of pharmaceuticals; biological research; clinical research in the field of clinical research in the field of transformational therapeutics; providing medical research and scientific research information in the field of filtration of exosomes from cultured cells or blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; medical laboratory diagnostics research services; information, advisory and consultancy services relating to the aforesaid; none of the foregoing in the fields of information technology and information technology systems; all of the foregoing excluding such goods or services in the fields of constipation, gut health, weight loss, appetite suppressants, dietetic preparations, and nutrition | ACTIVE | — |
| 044 | Pharmaceutical consultancy; medical diagnostic services; medical analysis for the diagnosis and treatment of persons and medical examinations; medical treatment services; medical screening; medical monitoring, testing, and inspection services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases; medical monitoring, testing, and inspection services relating to the diagnosis and treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; information, advisory and consultancy services relating to the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 11, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 11, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 2, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 2, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 31, 2026 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 6, 2026 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| May 6, 2026 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| May 6, 2026 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| May 6, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jul 29, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 29, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 29, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 29, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 29, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 24, 2025 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 2, 2025 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| May 2, 2025 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| May 2, 2025 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| May 2, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 1, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 1, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 1, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 23, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 23, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 23, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 18, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jun 18, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Mar 21, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 20, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 23, 2024 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jan 23, 2024 | ALIE | ASSIGNED TO LIE | — |
| Sep 13, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 12, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 1, 2023 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Aug 17, 2023 | NWAP | NEW APPLICATION ENTERED | — |